Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice

INTRODUCTION: In clinical trials, toxicity leading to discontinuation of tenofovir (TDF) is a rare occurrence (3% by two years)[1, 2]; however, in clinical practice it seems to be higher. Previous studies suggested that TDF toxicity is higher when it is co-administered with ritonavir-boosted proteas...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Int AIDS Soc
Päätekijät: Costarelli, Silvia, Cozzi-Lepri, Alessandro, Lapadula, Giuseppe, Bonora, Stefano, Madeddu, Giordano, Maggiolo, Franco, Antinori, Andrea, Gori, Andrea, D'Arminio-Monforte, Antonella
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: International AIDS Society 2014
Aiheet:
Poster Sessions – Abstract P039
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4224916/
https://ncbi.nlm.nih.gov/pubmed/25394078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7448/IAS.17.4.19571
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia